PET-CT Nanoimaging

The imaging and diagnosis of cancer are challenging and have become important due to rapid strides in the development of various imaging probes (Gambhir et al., J Nucl Med 42:1S–93S, 2001). Recent years have seen fast growth in technological developments and various newer radiolabeled nanoparticles (Jadvar and Parker, Clinical PET and PET/CT, Springer, Philadelphia, 2005), which have become important for the concept of personalized cancer nanomedicine. This has resulted in more frequent use of positron emission tomography (Karakatsanis et al., Phys Med Biol 58:7391–7418, 2013) (PET) in nanotechnology, leading to a more precise diagnosis due to their multifunctional nature (Hillner et al., J Nucl Med 53:831–837, 2012) and the mouldability of these nanomaterials, which has become important in the field of molecular imaging. In this chapter (Herrmann, PET Clin 9:331–338, 2014), we will discuss the role of radio nanomedicine (Acuff et al., J Nucl Med Technol 46:343–348, 2018), using nanomaterials for targeted molecular imaging (Unterrainer et al., Eur Radiol Exp 4:63, 2020). Newer developments have led to different radiolabeling protocols (Hirmas et al., Nuklearmedizin 60:V55, 2021), such as the use of nanoprobes in cancer theranostics. Clinical translation of (Liang et al., J Nanobiotechnol 18:154, 2020) radiolabeled nanomaterials with a special focus on the multidisciplinary use (Brandt et al., J Nucl Med 59:1500–1506, 2018) and applications of the newer agents in personalized medicine will also be discussed.